T1	CHEM 57 67	irbesartán
#1	AnnotatorNotes T1	C0288171; irbesartan; Organic Chemical · Pharmacologic Substance
T2	DISO 74 94	nefropatía diabética
#2	AnnotatorNotes T2	C0011881; Diabetic Nephropathy; Disease or Syndrome
T3	ANAT 949 957	arterial
#3	AnnotatorNotes T3	C0003842; Arteries; Body Part, Organ, or Organ Component | C1285085; Entire artery; Body Part, Organ, or Organ Component
T4	DISO 1154 1162	kaliemia
#4	AnnotatorNotes T4	C4229711; Normal potassium levels; Finding
T5	CHEM 241 253	receptor AT1
#5	AnnotatorNotes T5	C0529330; Receptor, Angiotensin, Type 1; Receptor · Amino Acid, Peptide, or Protein
T6	DISO 367 378	proteinuria
#6	AnnotatorNotes T6	C0033687; Proteinuria; Finding
T7	CHEM 419 429	irbesartán
#7	AnnotatorNotes T7	C0288171; irbesartan; Organic Chemical · Pharmacologic Substance
T8	DISO 436 456	nefropatía diabética
#8	AnnotatorNotes T8	C0011881; Diabetic Nephropathy; Disease or Syndrome
T9	PROC 490 555	Estudio prospectivo de intervención no controlado ni aleatorizado
#9	AnnotatorNotes T9	C0033522; Prospective Studies; Research Activity + C0184661; Interventional procedure; Therapeutic or Preventive Procedure + C0681868; Uncontrolled Study; Research Activity + C2985410; Nonrandomized; Research Activity
T10	PROC 1108 1123	perfil lipídico
#10	AnnotatorNotes T10	C0523744; Lipids measurement; Laboratory Procedure
T11	PROC 569 580	seguimiento
#11	AnnotatorNotes T11	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T12	PROC 596 622	tratamiento multifactorial
T13	CHEM 651 661	irbesartán
#12	AnnotatorNotes T13	C0288171; irbesartan; Organic Chemical · Pharmacologic Substance
T14	PROC 699 714	antropométricas
#13	AnnotatorNotes T14	C0003188; Anthropometry; Research Activity
T15	PROC 717 727	analíticas
#14	AnnotatorNotes T15	C0002778; Analysis of substances; Laboratory Procedure | C0814047; biological analysis and measurement; Laboratory Procedure
T16	DISO 795 810	diabetes tipo 2
#15	AnnotatorNotes T16	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T17	CHEM 1115 1123	lipídico
#16	AnnotatorNotes T17	C0023779; Lipids; Organic Chemical
T18	PROC 876 899	índice de masa corporal
#17	AnnotatorNotes T18	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T19	PROC 1260 1288	filtrado glomerular estimado
#18	AnnotatorNotes T19	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T20	PROC 1517 1520	IMC
#19	AnnotatorNotes T20	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T21	DISO 1355 1366	proteinuria
#20	AnnotatorNotes T21	C0033687; Proteinuria; Finding
T22	PROC 1523 1546	hemoglobina glucosilada
#21	AnnotatorNotes T22	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T23	PROC 901 904	IMC
#22	AnnotatorNotes T23	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T24	DISO 1673 1692	efectos secundarios
#23	AnnotatorNotes T24	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T25	PROC 1710 1721	tratamiento
#24	AnnotatorNotes T25	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T26	DISO 1728 1748	nefropatía diabética
#25	AnnotatorNotes T26	C0011881; Diabetic Nephropathy; Disease or Syndrome
T27	CHEM 1785 1795	irbesartán
#26	AnnotatorNotes T27	C0288171; irbesartan; Organic Chemical · Pharmacologic Substance
T28	DISO 1840 1851	proteinuria
#27	AnnotatorNotes T28	C0033687; Proteinuria; Finding
T29	DISO 1886 1922	insuficiencia renal crónica terminal
#28	AnnotatorNotes T29	C2316810; Chronic kidney disease stage 5; Disease or Syndrome
T30	CHEM 172 220	antagonistas del receptor AT1 de angiotensina II
#29	AnnotatorNotes T30	C1449680; Angiotensin II Type 1 Receptor Blockers; Pharmacologic Substance
T31	ANAT 389 394	renal
#30	AnnotatorNotes T31	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T32	ANAT 891 899	corporal
#31	AnnotatorNotes T32	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T33	PROC 941 967	presión arterial sistólica
#32	AnnotatorNotes T33	C1306620; Systolic blood pressure measurement; Diagnostic Procedure
T34	PROC 1182 1192	creatinina
#33	AnnotatorNotes T34	C0201975; Creatinine measurement; Laboratory Procedure
T35	ANAT 1900 1905	renal
#34	AnnotatorNotes T35	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T36	Date 25 38	a largo plazo
T37	Dose 42 53	dosis altas
#35	AnnotatorNotes T37	C0444956; High dose; Quantitative Concept
T38	Dose 157 168	dosis altas
#36	AnnotatorNotes T38	C0444956; High dose; Quantitative Concept
T39	Duration 559 565	3 años
T40	Dose 633 639	600 mg
T41	Frequency 640 647	diarios
T42	Age 836 850	57,1 ± 10 años
T49	Duration 1906 1913	crónica
#37	AnnotatorNotes T49	C0205191; chronic; Temporal Concept
T50	PHYS 381 394	función renal
#38	AnnotatorNotes T50	C0232804; Renal function; Organ or Tissue Function
T51	Dose 399 415	dosis ultraaltas
T43	Neg_cue 1633 1639	Ningún
T44	Dose 1765 1781	dosis ultraaltas
T47	Dose 308 328	dosis convencionales
T52	LIVB 776 785	pacientes
#39	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	LIVB 1474 1483	pacientes
#40	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	LIVB 863 870	hombres
#41	AnnotatorNotes T54	C0025266; Male population group; Population Group
T55	LIVB 1640 1648	paciente
#42	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T45	PHYS 941 957	presión arterial
#43	AnnotatorNotes T45	C0005823; Blood Pressure; Organism Function
T46	PHYS 1260 1279	filtrado glomerular
#44	AnnotatorNotes T46	C0232809; Glomerular filtration; Organ or Tissue Function
T48	PROC 941 957;998 1008	presión arterial diastólica
#45	AnnotatorNotes T48	C1305849; Diastolic blood pressure measurement; Diagnostic Procedure
T56	ANAT 1269 1279	glomerular
#46	AnnotatorNotes T56	C0022663; Kidney Glomerulus; Body Part, Organ, or Organ Component | C1284485; Entire glomerulus; Body Part, Organ, or Organ Component
T57	Observation 1492 1509	normoalbuminúrico
#47	AnnotatorNotes T57	C0860865; Albumin normal; Finding
T58	CONC 731 757	inicio y final del estudio
#48	AnnotatorNotes T58	C2983670; Study End Date; Temporal Concept + C2348558; Study Start Date; Temporal Concept
T59	CONC 1086 1103	final del estudio
#49	AnnotatorNotes T59	C2983670; Study End Date; Temporal Concept
T60	Quantifier_or_Qualifier 95 106	establecida
#50	AnnotatorNotes T60	C0443211; Established; Qualitative Concept
T61	Quantifier_or_Qualifier 457 468	establecida
#51	AnnotatorNotes T61	C0443211; Established; Qualitative Concept
T62	Quantifier_or_Qualifier 1749 1760	establecida
#52	AnnotatorNotes T62	C0443211; Established; Qualitative Concept
T64	Observation 1866 1876	progresión
#53	AnnotatorNotes T64	C1457868; Worse; Finding
T63	Observation 1649 1668	abandonó el estudio
#54	AnnotatorNotes T63	C0422727; Patient withdrawn from trial; Finding (?)
T65	Observation 1 24	Efectos renoprotectores
T66	CONC 675 697	variables demográficas
#55	AnnotatorNotes T66	C0011292; Demographic Factors; Idea or Concept
T67	Neg_cue 1163 1165	no
T68	CONC 1166 1177	se modificó
#56	AnnotatorNotes T68	C0436315; Symptom modification; Qualitative Concept (?)
A1	Assertion T55 Negated
R2	Has_Dose_or_Strength Arg1:T1 Arg2:T37
R3	Has_Dose_or_Strength Arg1:T30 Arg2:T38
R4	Has_Dose_or_Strength Arg1:T30 Arg2:T47
R6	Has_Dose_or_Strength Arg1:T13 Arg2:T40
R7	Has_Dose_or_Strength Arg1:T27 Arg2:T44
R8	Has_Duration_or_Interval Arg1:T11 Arg2:T39
R10	Has_Age Arg1:T54 Arg2:T42
R11	Has_Frequency Arg1:T13 Arg2:T41
R1	Negation Arg1:T43 Arg2:T55
R12	Has_Age Arg1:T52 Arg2:T42
R14	Experiences Arg1:T52 Arg2:T16
R5	Has_Dose_or_Strength Arg1:T7 Arg2:T51
R9	Location_of Arg1:T3 Arg2:T33
R15	Experiences Arg1:T52 Arg2:T18
R17	Experiences Arg1:T52 Arg2:T23
R19	Experiences Arg1:T55 Arg2:T24
R20	Location_of Arg1:T31 Arg2:T50
R21	Location_of Arg1:T3 Arg2:T45
R22	Location_of Arg1:T56 Arg2:T46
R23	Location_of Arg1:T35 Arg2:T29
R24	Has_Duration_or_Interval Arg1:T29 Arg2:T49
R25	Location_of Arg1:T3 Arg2:T48
R26	Experiences Arg1:T53 Arg2:T57
R27	Used_for Arg1:T27 Arg2:T25
R28	Used_for Arg1:T13 Arg2:T12
R29	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T60
R30	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T61
R31	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T62
R32	Overlap Arg1:T15 Arg2:T58
R33	Overlap Arg1:T14 Arg2:T58
R18	Overlap Arg1:T48 Arg2:T59
R34	Overlap Arg1:T33 Arg2:T59
R36	Overlap Arg1:T65 Arg2:T36
A2	Assertion T68 Negated
R13	Negation Arg1:T67 Arg2:T68
R16	Causes Arg1:T8 Arg2:T6
T69	Quantifier_or_Qualifier 529 539	controlado
A3	Assertion T69 Negated
T70	Quantifier_or_Qualifier 543 555	aleatorizado
A4	Assertion T70 Negated
T71	Neg_cue 540 542	ni
R37	Negation Arg1:T71 Arg2:T70	
T72	Neg_cue 526 528	no
R38	Negation Arg1:T72 Arg2:T69	
R39	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T69	
R40	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T70	
T73	Result_or_Value 909 923	30,7 ± 5 kg/m2
R41	Has_Result_or_Value Arg1:T23 Arg2:T73	
R42	Has_Result_or_Value Arg1:T18 Arg2:T73	
T74	Spec_cue 255 262	debería
T75	Observation 280 290	beneficios
A5	Assertion T75 Speculated
#57	AnnotatorNotes T75	C4049461; Unexpected beneficial therapeutic response; Finding (?)
R43	Speculation Arg1:T74 Arg2:T75	
T76	Quantifier_or_Qualifier 272 279	mayores
A6	Assertion T76 Speculated
R44	Has_Quantifier_or_Qualifier Arg1:T75 Arg2:T76	
R45	Speculation Arg1:T74 Arg2:T76	
R46	Experiences Arg1:T54 Arg2:T18	
R47	Experiences Arg1:T54 Arg2:T23	
R48	Experiences Arg1:T54 Arg2:T16	
R49	Location_of Arg1:T56 Arg2:T19	
T77	Observation 353 360	efectos
#58	AnnotatorNotes T77	C1518681; Outcome of Therapy; Finding (?)
R50	Causes Arg1:T1 Arg2:T65	
R51	Causes Arg1:T7 Arg2:T77	
R52	Location_of Arg1:T32 Arg2:T18	
R53	Location_of Arg1:T32 Arg2:T23	
#59	AnnotatorNotes T76	C1704243; Greater; Quantitative Concept
#60	AnnotatorNotes T69	C4553389; Study Control; Conceptual Entity
#61	AnnotatorNotes T36	C0443252; Long-term; Temporal Concept
A7	Experiencer T52 Patient
A8	Experiencer T54 Patient
A9	Experiencer T53 Patient
A10	Experiencer T55 Patient
